Cargando…
Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab
The limited efficacy of the currently available medical therapies in a proportion of patients with Crohn’s disease has led to the research and development of molecules that can block new inflammatory pathways. Ustekinumab is a fully human IgG1 monoclonal antibody which targets the common p40 subunit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697448/ https://www.ncbi.nlm.nih.gov/pubmed/29180886 http://dx.doi.org/10.2147/CEG.S110546 |